Rhode Island Chronicle

Wet Age-Related Macular Degeneration Pipeline Insight Report 2023 (Updated)

 Breaking News
  • No posts were found

Wet Age-Related Macular Degeneration Pipeline Insight Report 2023 (Updated)

September 12
23:00 2023
Wet Age-Related Macular Degeneration Pipeline Insight Report 2023 (Updated)

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report

  • DelveInsight’s Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
  • The leading companies working in the Wet Age-Related Macular Degeneration market include Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
  • Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
  • On July 2023, EyePoint Pharmaceuticals Inc. announced a study of Phase 2 Clinical Trials for Eyp-1901 and Aflibercept 2Mg/0.05Ml Inj,Oph. This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at two dose levels: 2060 ug and 3090 ug against Aflibercept.
  • On September 2023, Neuracle Genetics Inc. announced a study of Phase 1 & 2 Clinical Trials for NG101 AAV gene therapy. This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).

 

Request a sample and discover the recent advances in Wet Age-Related Macular Degeneration Treatment Drugs @ Wet Age-Related Macular Degeneration Pipeline Report

 

The Wet Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Wet Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Wet Age-Related Macular Degeneration clinical trial landscape.

 

Wet Age-Related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative).

 

Find out more about Wet Age-Related Macular Degeneration Treatment Drugs @ Drugs for Wet Age-Related Macular Degeneration Treatment

 

Wet Age-Related Macular Degeneration Emerging Drugs Profile

  • Abicipar pegol: Molecular Partners
  • SOK583A1: Sandoz
  • BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.
  • ADVM-022: Adverum Biotechnologies

 

Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment

The Wet Age-Related Macular Degeneration pipeline report proffers an integral view of the Wet Age-Related Macular Degeneration emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Wet Age-Related Macular Degeneration Pipeline Therapies @ Wet Age-Related Macular Degeneration Clinical Trials Assessment

 

Scope of the Wet Age-Related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Wet Age-Related Macular Degeneration Companies- Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
  • Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.

 

Dive deep into rich insights for new drugs for Wet Age-Related Macular Degeneration Treatment, Visit @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Wet Age-related Macular Degeneration: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Wet Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Abicipar pegol: Molecular Partners
  9. Late Stage Products (Phase III)
  10. SOK583A1: Sandoz
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. ADVM-022: Adverum Biotechnologies
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Wet Age-related Macular Degeneration- Unmet Needs
  23. Wet Age-related Macular Degeneration- Market Drivers and Barriers
  24. Appendix

 

For further information on the Wet Age-Related Macular Degeneration Pipeline therapeutics, reach out to Wet Age-Related Macular Degeneration Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Categories